BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/23/2022 9:24:32 AM | Browse: 853 | Download: 2036
 |
Received |
|
2021-06-22 22:03 |
 |
Peer-Review Started |
|
2021-06-22 22:07 |
 |
First Decision by Editorial Office Director |
|
2021-07-16 05:52 |
 |
Return for Revision |
|
2021-07-16 05:52 |
 |
Revised |
|
2021-08-04 02:34 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2022-01-15 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2022-01-17 05:34 |
 |
Articles in Press |
|
2022-01-17 05:34 |
 |
Edit the Manuscript by Language Editor |
|
2021-12-19 01:32 |
 |
Typeset the Manuscript |
|
2022-02-16 13:49 |
 |
Publish the Manuscript Online |
|
2022-02-23 09:24 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Agustín Falco, Mariano Leiva, Albano Blanco, Guido Cefarelli, Andrés Rodriguez, Juan Melo, Federico Cayol, Manglio Miguel Rizzo, Alejandro Sola, Hernán Rodríguez Montani, Matías Chacon, Diego Enrico and Federico Waisberg |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Agustín Falco, MD, Staff Physician, Department of Medical Oncology, Head and Neck Unit, Alexander Fleming Cancer Institute, Cramer 1180, Buenos Aires 1428, Argentina. afalco@alexanderfleming.org |
| Key Words |
Recurrent and/or metastatic head and neck cancer; TPEx schema; Cetuximab; Docetaxel; Cisplatin; First-line |
| Core Tip |
We evaluated the safety and efficacy of the combination platinum, taxanes, and cetuximab scheme as a first-line therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck in a real-world setting. Among the 24 patients included, the median progression-free survival was 6.9 mo (95% confidence interval: 6.5-7.3), and the overall survival rate at 12 mo was 82.4%, which was consistent with previous clinical trials. Patients with documented tumor response showed statistically better progression-free survival than those with disease stabilization or progression (P = 0.034). The combination platinum, taxanes, and cetuximab regimen was adequately tolerated by most of the analyzed patients, as the incidence of grade 3-4 adverse events was surprisingly lower than expected (25%). |
| Publish Date |
2022-02-23 09:24 |
| Citation |
Falco A, Leiva M, Blanco A, Cefarelli G, Rodriguez A, Melo J, Cayol F, Rizzo MM, Sola A, Rodríguez Montani H, Chacon M, Enrico D, Waisberg F. First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study. World J Clin Oncol 2022; 13(2): 147-158
|
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i2/147.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i2.147 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.